Peripheral Blood Lymphocyte Subsets Predict the Efficacy of Immune Checkpoint Inhibitors in Non–Small Cell Lung Cancer

BACKGROUND: Non–small cell lung cancer (NSCLC) has entered the era of immunotherapy. However, only partial patients were able to benefit from immune checkpoint inhibitors (ICIs). Currently, biomarkers for predicting patients’ response to ICIs are primarily tumor tissue dependent and have limited acc...

Descripción completa

Detalles Bibliográficos
Autores principales: Miao, Kang, Zhang, Xiaotong, Wang, Hanping, Si, Xiaoyan, Ni, Jun, Zhong, Wei, Zhao, Jing, Xu, Yan, Chen, Minjiang, Pan, Ruili, Wang, Mengzhao, Zhang, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9283649/
https://www.ncbi.nlm.nih.gov/pubmed/35844502
http://dx.doi.org/10.3389/fimmu.2022.912180

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9283649/
https://www.ncbi.nlm.nih.gov/pubmed/35844502
http://dx.doi.org/10.3389/fimmu.2022.912180

Ejemplares similares